BG-12 – update

I had written about new MS drug discoveries last year in September ( ) where I briefly mentioned Biogen Idec’s BG-12 oral drug (among many others: ) for MS.

It now seems that the drug showed promising MRI results in MS patients with regards to being able to reduce inflammation and its potential neuroprotective abilities. From the Medical News Today article (Dec 8th):

BG-12 has been shown to activate the Nrf2 transcriptional pathway, which pre-clinical studies have shown defends against oxidative-stress induced neuronal death, protects the blood-brain barrier and supports maintenance of myelin integrity in the central nervous system. Central nervous system inflammation and damage may trigger the symptoms common in RRMS such as fatigue, cognitive deterioration and physical disability. Because of BG-12’s unique effect on the Nrf2 pathway and its oral delivery, BG-12 is also being considered for future MS combination therapy studies.”

I must say, there are interesting discoveries every day : )

hope is last to die! ; )


1 Comment (+add yours?)

  1. maggsbunny
    Dec 13, 2009 @ 10:55:16

    Excellent post! It is an exciting time for all us MS-ers. Hope is alive and well.


Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: